Showing results (51-60 of 66) with videos related to
Sort By:
Pageof 7
The Oncologist|May 21, 2017
Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301Eisaku Miyauchi, Akira Inoue, Kazuhiro Usui, et al.International Journal of Clinical Oncology|November 13, 2020
Randomized phase II trial of carboplatin + nab-paclitaxel versus cisplatin + gemcitabine for chemotherapy-naïve squamous cell carcinoma: North Japan lung cancer study group 1302Yosuke Kawashima, Toshiyuki Harada, Yuka Fujita, et al.Journal of Immunology (Baltimore, Md. : 1950)|February 8, 2003
Mouse SWAM1 and SWAM2 are antibacterial proteins composed of a single whey acidic protein motifKoichi Hagiwara, Tohru Kikuchi, Yoshiyuki Endo, et al.Lung Cancer (Amsterdam, Netherlands)|May 7, 2013
Randomized phase II trial of uracil/tegafur and cisplatin versus vinorelbine and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-small-cell lung cancer: NJLCG 0601Shunichi Sugawara, Makoto Maemondo, Motoko Tachihara, et al.Lung Cancer (Amsterdam, Netherlands)|August 28, 2016
A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013AKazuhiro Usui, Shunichi Sugawara, Masaru Nishitsuji, et al.The Oncologist|April 1, 2014
Randomized phase II trial comparing carboplatin plus weekly paclitaxel and docetaxel alone in elderly patients with advanced non-small cell lung cancer: north japan lung cancer group trial 0801Makoto Maemondo, Akira Inoue, Shunichi Sugawara, et al.The American Journal of Surgical Pathology|July 26, 2016
Solitary Pulmonary Capillary Hemangioma of Adult Cases: Clinicopathologic Characteristics as an Unrecognized EntityHirotsugu Hashimoto, Atsushi Kurata, Masachika Fujiwara, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2009
First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapyAkira Inoue, Kunihiko Kobayashi, Kazuhiro Usui, et al.JTO Clinical and Research Reports|October 17, 2024
The Whole Picture of First-Line Osimertinib for EGFR Mutation-Positive Advanced NSCLC: Real-World Efficacy, Safety, Progression Pattern, and Posttreatment Therapy (Reiwa Study)Kageaki Watanabe, Yukio Hosomi, Katsuhiko Naoki, et al.Lung Cancer (Amsterdam, Netherlands)|September 25, 2014
A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903)Yoshifumi Matsumoto, Makoto Maemondo, Yoshiki Ishii, et al.Pageof 7